COMMUNIQUÉS West-GlobeNewswire

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
04/11/2025
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP [...]
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
04/11/2025
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80 [...]
Precipio Announces Q3-2025 Shareholder Update Call
04/11/2025
Conference Call to be held on November 17th, 2025 at 5:00 PM EST NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2025 [...]
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
04/11/2025
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the [...]
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
04/11/2025
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK ™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking [...]
Pacific Health Care Organization, Inc. Reports its Third Quarter 2025 Financial Results
04/11/2025
Irvine, CA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q [...]
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
04/11/2025
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment [...]
Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®
04/11/2025
First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus [...]
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
04/11/2025
Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit [...]
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
04/11/2025
– Mean weight loss of 19.2% I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6% I at 8 mg [...]
Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference
04/11/2025
CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at [...]
Fueling Discovery: Misophonia Research Fund Launches New Team Science Award, Expands 2026 Funding Opportunities, and Announces Latest Grantee Cohort
04/11/2025
CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Misophonia Research Fund (MRF), an initiative of the REAM Foundation, announces a major expansion of its support of misophonia research – launching the first-ever team [...]
Édition 2025 du congrès mondial du collectif médical polonais « Save a Life » : une mission d’envergure mondiale répondant à l’objectif de faire progresser l’expertise en sauvetage de vies
04/11/2025
Un rassemblement des professionnels de santé polonais répartis à travers le monde placé sous le signe de la coopération internationale et de l’excellence médicale VARSOVIE, Pologne, 04 nov. 2025 (GLOBE NEWSWIRE) -- Du [...]
Bionet Launches O’Pet Curv: A New Standard in Veterinary Wireless Monitoring
04/11/2025
TUSTIN, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bionet America, Inc ., a leader in veterinary medical devices, has introduced the new O’Pet Curv, a compact, cloud-connected wireless monitoring system that allows [...]
Coloplast Finance B.V. - Annual Report, 2024/25
04/11/2025
Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
04/11/2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will [...]
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
04/11/2025
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other [...]
Equillium to Participate in Upcoming Investor Conferences
04/11/2025
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
04/11/2025
Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced [...]

Pages